Treatment of Stage IV Lung Cancer [Exon 19 deletion positive] : research

Discussion in 'General Discussion' started by Jason, Feb 11, 2015.

  1. Jason

    Jason Developer / Handyman Staff Member

    Gefitinib (Iressa)
    - Genomics: pt has an Exon 19 deletion
    - effective but resistant mutations can develop. (around 9 months).

    Mets to: local rib, mediastinum, liver

    Trials in NZ: cancer New Zealand&recr=Open

    EGFR Exon 19 Deletion in Non-Small Cell Lung Cancer

    EGFR exon 19 deletions are in-frame deletions occurring within exon 19, which encodes part of the kinase domain. This mutation occurs with a frequency of approximately 48% in EGFR mutant lung tumors (Mitsudomi and Yatabe 2010).

    - Multiple EGFR tyrosine kinase inhibitors (TKIs) have been developed or are in development:

    First-generation: Gefitinib (Iressa) and erlotinib (Tarceva). Icotinib is another reversible inhibitor like gefitinib and erlotinib that was recently developed and is available only in China.

    Second-generation: Afatinib (Gilotrif), dacomitinib, neratinib. These are irreversible inhibitors with activity against both EGFR and other ERBB family members.

    Third-generation: CO-1686, AZD9291. These are mutant-selective as they were designed to target mutant EGFR better than wild type EGFR, while the agents above were originally designed to target wild type EGFR.
  2. Graham

    Graham Developer Staff Member

    Unfortunately no trials of AZD9291 here.

Share This Page